NASDAQ:ONCR Oncorus (ONCR) Stock Price, News & Analysis → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free ONCR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.13▼$0.2050-Day Range$0.01▼$0.1352-Week Range$0.01▼$0.47Volume135,900 shsAverage Volume1.33 million shsMarket Capitalization$3.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisEarningsHeadlinesInsider TradesSocial MediaStock AnalysisEarningsHeadlinesInsider TradesSocial Media Get Oncorus alerts: Email Address Ad Stansberry ResearchBiggest hedge fund manager has huge warning for U.S. dollarPrescient CEO Makes Shocking New Prediction Known for his eerily accurate market calls over the years, this CEO has just revealed his newest prediction about "America's New Money."Get the details before it's taken offline. About Oncorus Stock (NASDAQ:ONCR)Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company develops ONCR-021 for the treatment of non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic thyroid cancer; and ONCR-788 for the treatment of small cell lung cancer, neuroendocrine prostate, and other neuroendocrine cancers. Oncorus, Inc. was incorporated in 2015 and is headquartered in Andover, Massachusetts.Read More Ad Stansberry ResearchBiggest hedge fund manager has huge warning for U.S. dollarPrescient CEO Makes Shocking New Prediction Known for his eerily accurate market calls over the years, this CEO has just revealed his newest prediction about "America's New Money."Get the details before it's taken offline. ONCR Stock News HeadlinesFebruary 26, 2024 | benzinga.comOncorus Inc rdinary Shares Stock (OTC:ONCR) Dividends: History, Yield and DatesDecember 29, 2023 | uk.finance.yahoo.comOncorus, Inc. (ONCR) stock price, news, quote & history – Yahoo FinanceMay 10, 2024 | Stansberry Research (Ad)Do This Today BEFORE Biden Wins in NovemberDiscover "U.S.'s New Money" Before Biden Wins A new form of money has emerged in America, and it's making some folks wildly rich… (Musk and Bezos both use it).December 18, 2023 | investing.comComera Life Sciences Holdings IncOctober 28, 2023 | morningstar.comOncorus Inc Ordinary SharesOctober 16, 2023 | investing.comONCR Historical DataJune 16, 2023 | msn.comWhat's Going On With Oncorus (ONCR) Stock Friday?June 2, 2023 | msn.comOncorus could file for bankruptcy as most employees laid off; down 43%May 10, 2024 | Stansberry Research (Ad)Do This Today BEFORE Biden Wins in NovemberDiscover "U.S.'s New Money" Before Biden Wins A new form of money has emerged in America, and it's making some folks wildly rich… (Musk and Bezos both use it).June 1, 2023 | finance.yahoo.comOncorus Announces Workforce Reduction PlanMay 23, 2023 | finanznachrichten.deOncorus, Inc.: Oncorus Reports First Quarter 2023 Financial Results and Provides Business UpdatesMay 22, 2023 | msn.comRecap: Oncorus Q1 EarningsMay 22, 2023 | finance.yahoo.comOncorus Reports First Quarter 2023 Financial Results and Provides Business UpdatesMarch 24, 2023 | finanznachrichten.deOncorus, Inc.: Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesMarch 24, 2023 | finance.yahoo.comOncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesMarch 15, 2023 | bizjournals.comFor some biotechs moving on from SVB, not all traditional banks are an optionMarch 11, 2023 | markets.businessinsider.comRoku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed BankJanuary 4, 2023 | finance.yahoo.comOncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug CandidatesNovember 30, 2022 | marketwatch.comOncorus Shares Plumb New Depths on Job Cuts, Portfolio Reshaping >ONCRNovember 30, 2022 | finance.yahoo.comOncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with CancerNovember 23, 2022 | finance.yahoo.comOncorus to Participate in Upcoming Investor ConferencesNovember 18, 2022 | finance.yahoo.comOncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual MeetingNovember 7, 2022 | finance.yahoo.comOncorus, Inc. (ONCR) Moves to Buy: Rationale Behind the UpgradeNovember 2, 2022 | msn.comRecap: Oncorus Q3 EarningsOctober 8, 2022 | fool.comOncorus, Inc. (NASDAQ: ONCR)October 7, 2022 | finance.yahoo.comOncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of CancerOctober 5, 2022 | theglobeandmail.comOncorus: Top 10 Undervalued Healthcare Stocks on NAS (ONCR)See More Headlines Receive ONCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncorus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/22/2023Today5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ONCR CUSIPN/A CIK1671818 Webwww.oncorus.com Phone339-240-3330FaxN/AEmployees64Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.33 per share Price / Book0.05Miscellaneous Outstanding Shares26,090,000Free Float21,633,000Market Cap$3.29 million OptionableOptionable Beta3.60 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Craig R. Jalbert CIRA (Age 61)CEO, President, CFO, Treasurer, Secretary & Director Chris GermanControllerKey CompetitorsAridis PharmaceuticalsNASDAQ:ARDSBiophytisNASDAQ:BPTSYNovaBay PharmaceuticalsNYSE:NBYPhaseBio PharmaceuticalsNASDAQ:PHASClever LeavesNASDAQ:CLVRView All Competitors ONCR Stock Analysis - Frequently Asked Questions How were Oncorus' earnings last quarter? Oncorus, Inc. (NASDAQ:ONCR) released its quarterly earnings data on Monday, May, 22nd. The company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($0.70) by $0.48. What other stocks do shareholders of Oncorus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oncorus investors own include Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV), Atlas Air Worldwide (AAWW). When did Oncorus IPO? Oncorus (ONCR) raised $87 million in an IPO on Friday, October 2nd 2020. The company issued 5,800,000 shares at a price of $14.00-$16.00 per share. Jefferies, Evercore ISI and Piper Sandler served as the underwriters for the IPO. This page (NASDAQ:ONCR) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsMissed NVDA? Buy this AI stock NOWChaikin AnalyticsCharles Payne Demystifies OptionsUnstoppable ProsperityYou need to know these two things about AI stocks ASAP…InvestorPlaceGold ManiaStansberry ResearchShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncorus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
